Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin

By J. Hanna, Marius Wernig, S. Markoulaki, Chiao‐Wang Sun, Alexander Meissner, John P. Cassady, C. Beard, T. Brambrink, Li‐Chen Wu, T. Townes and 1 more. Science, 2007

1,589 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1549123024fd915edfbc1b726251c6e0f87c7645

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs (2010, background): “Finally, the definition and characterization of a naïve pluripotent state in human cells may expand the capabilities for using human ESCs and iPSCs in regenerative medicine and disease modeling both in vitro and in vivo (42, 43).”
Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease (2008, background): “In a recent proof of principle study, we could demonstrate a therapeutic benefit of iPS cell-derived hematopoietic cells in a humanized mouse model of sickle cell anemia (13).”
Epigenetic reprogramming and induced pluripotency (2009, background): “, 2008c) and sickle cell anemia (Hanna et al., 2007) in mouse models.”
Somatic cell reprogramming and transitions between pluripotent states: facts, hypotheses, unresolved issues (2010, neutral): “, 1998), and this technology, combined with the direct reprogramming of somatic cells to pluripotent cells (Takahashi and Yamanaka, 2006), is now paving the way for ‘‘personalized’’ regenerative medicine (Hanna et al., 2007).”
Induced pluripotency: history, mechanisms, and applications. (2010, background): “Specifically, Jaenisch and colleagues (Hanna et al. 2007) showed that iPSCs can be used to rescue the defects seen in an animal model of sickle cell anemia.”
Immunogenicity of induced pluripotent stem cells. (2011, positive): “For example, hematopoietic stem cells and neuronal precursor cells from iPSCs could relieve sickle cell anemia and spinal cord injury, respectively.(6,7) The immunogenicity of the differentiated cells should be assessed.”
Gene therapy clinical trials worldwide to 2012 – an update (2013, background): “In another study, utilising a humanised mouse model of sickle cell anaemia, mice were rescued following transplantation with haematopoietic progenitors that were corrected by gene-specific targeting [83].”
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. (2008, background): “Indeed, iPS cells have recently been shown in a proof-of-principle experiment to treat sickle cell anemia in mice (Hanna et al., 2007).”